SCHEMBL25518503

SCHEMBL25518503

CCCCC(CCC)CCOCCOCCOCCOCCOCCOCCN1CCN(CCCC(C)C)CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.33
HTT P42858 1/20 0.32
GNAI3 P08754 1/20 0.32
GNAO1 P09471 1/20 0.32
GNAI1 P63096 1/20 0.32
HRH2 P25021 1/20 0.32
HRH1 P35367 1/20 0.32
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
LTA4H P09960 1/20 0.30
CYP1A2 P05177 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM1 P11229 1/20 0.30
HTR2A P28223 1/20 0.30
MAPK1 P28482 1/20 0.30
SCN1A P35498 1/20 0.30
HTR2B P41595 1/20 0.30
KCNH2 Q12809 1/20 0.30
SCN2A Q99250 1/20 0.30
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25118180 0.85 HRH2 (0.38) USP2HTTGNAI3GNAO1GNAI1
SCHEMBL25512781 0.83 HTT (0.37) USP2HTTGNAI3GNAO1GNAI1
SCHEMBL20850751 0.83 KDM4E (0.37) HTTALDH1A1KDM4EGBA1
SCHEMBL22963141 0.83 KDM4E (0.37) HTTALDH1A1KDM4EGBA1
SCHEMBL24673304 0.77 HRH3 (0.35) USP2HTTGNAI3GNAO1GNAI1
SCHEMBL23205212 0.76 HTT (0.35) HTTGNAI3GNAO1GNAI1HRH2
SCHEMBL9945689 0.76 GNAI3 (0.45) USP2GNAI3GNAO1GNAI1SIGMAR1
SCHEMBL22963144 0.75 GBA1 (0.38) HTTALDH1A1KDM4ELTA4HGBA1
SCHEMBL26504295 0.74 GNAI3 (0.53) USP2GNAI3GNAO1GNAI1KDM4E
SCHEMBL25122590 0.74 GNAI3 (0.44) GNAI3GNAO1GNAI1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148436-A2 NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF SHENZHEN UNIVERSITY (CN) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148436-A2 NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF IFNG, IFNAR1, STING1 USP2 1344/4885HTT 4539/4885GNAI3 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.